Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program

ABSTRACT: This study evaluates physical performance in cancer outpatients during a multimodal therapy. Half of the patients will receive physical exercise und nutrition program in combination with a specially formulated whey protein supplement, while the other half will receive standard care.

DISEASE(S): Gastrointestinal Neoplasms,Lung Cancer,Carcinoma,Gastro-intestinal Cancer,Mesothelioma,Urothelial Carcinoma,Breast Cancer,Ovarian Cancer,Pleural Mesothelioma,Carcinoma, Renal Cell,Prostate Cancer,Renal Cell Carcinoma,Intestinal Neoplasms

PROVIDER: 2200836 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Homo sapiens

Project description:Half-Half experiments

| PRJNA203103 | ENA

Postoperative Diet With Hyperproteic Supplement Versus a Supplement With Imunonutrients, in Colorectal Cancer Surgery

Project description:The study is a randomized, multicentric, double-blind, controlled with active comparator, parallel groups trial, to demonstrate the non-inferiority in efficacy and therapeutic safety of the postoperative diet with oligomeric-hyperprotéic-normocaloric supplement (group 1) versus a supplement with imunonutrients (group 2), in a multimodal rehabilitation regimen (ERAS) of colorectal surgery for colon cancer and that arrive at surgery in a normal nutritional state or without any intervention on their nutritional status, according to the scale Malnutrition Screening Tool (MST).

| 2313986 | ecrin-mdr-crc

Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom

Project description:Primary objectives: Primäres Studienziel der Phase IDefinition der empfohlenen Dosis von Capecitabin und Oxaliplatin bei gleichzeitiger Therapie mit Bevacizumab und Imatinib. Primäres Studienziel der Phase IIMachbarkeit und Verträglichkeit der in der Phase I ermittelten Dosis der Kombination aus XELOX mit Bevacizumab und Imatinib anhand der Bestimmung der Sicherheit und der Nebenwirkungen und Toxizitäten der Kombinationstherapie. Primary endpoints: Phase I Definition der empfohlenen Dosis von Capecitabin und Oxaliplatin bei gleichzeitiger Therapie mit Imatinib und Bevacizumab. Phase II Bestimmung der Sicherheit und der Nebenwirkungen und Toxizitäten der Kombinationstherapie mit Capecitabin, Oxaliplatin, Imatinib und Bevacizumab

| 2521499 | ecrin-mdr-crc

Single-cell RNA-seq of human peripheral blood mononuclear cells in COVID-19

Project description:We carried out sex-balanced sampling of peripheral blood mononuclear cells (PBMCs) from confirmed COVID-19 inpatients (hospitalized) and outpatients (infected), uninfected close contacts (exposed), and healthy controls.

2021-04-15 | GSE171555 | GEO

Dietary supplement

Project description:effect of dietary supplement on rumen bacterial composition of yak.

| PRJEB36248 | ENA

Dietary supplement

Project description:16S sequencing during in vitro rumen fermentation of Yaks with different alpine plants

| PRJEB50152 | ENA

Dietary supplement

Project description:Effects of condensed tannin content in Alpine plants on rumen microorganisms of yak in vitro fermentation

| PRJEB50069 | ENA

The effects of a novel oral nutritional supplement as compared to standard care on body composition, physical function and skeletal muscle mRNA expression in Dutch older adults with (or at risk of) undernutrition

Project description:In a randomized controlled trial, 82 older adults (>65y) with (or at risk of) undernutrition (n=82) were randomly allocated to 12 weeks of supplementation with a novel supplement (586 kcal, 22 g protein of which 50% whey and 50% casein, 206 mg ursolic acid, 7 g free BCAAs, 11 µg vitamin D) or standard care (600 kcal, 24g protein of which 100% casein, 4 µg vitamin D). Body weight increased significantly in the 12 weeks, both in the intervention group (+1.6 ± 0.2 kg, p<.0001) and in the standard care group (+1.8 ± 0.2 kg, p<.0001). Gait speed during 4m and 400m tests improved over time in the intervention group, whereas the standard care showed no improvements (time*treatment effects 400m: p=0.038 and 4m: p=0.048). Gene sets related to mitochondrial functioning were strongly upregulated in the participants receiving the intervention product. We showed that a novel oral nutritional supplement improves gait speed in older adults via improvements in mitochondrial functioning.

2021-04-06 | GSE136395 | GEO

Project description:Whey prokaryota

| PRJNA1194369 | ENA

Expression profiles of microRNA in bovine raw milk exosome and supernatant without exosome [miRNA array]

Project description:We have reported that microRNAs are present in human, bovine, and rat milk whey. Milk whey miRNAs were resistant to acidic condition and to RNase. Thus, milk miRNAs were thought to be present packaged into membrane vesicles like exosome. However, body fluid miRNAs have been reported that there are in different forms. To clarify which miRNAs species are exist in exosome and which species are exist in another form, we used bovine raw milk and purified total RNA from exosome fraction and ultracentrifugated supernatant fraction, and analyzed by miRNA microarray.

2015-03-09 | GSE61976 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data